Brief: Neovacs FY Net Loss at EUR 14.8 Mln, Expects to Report Results Of Phase IIB Clinical Trial In Lupus In Mid-2018

Neovacs SA

30/03/2018 06:30

March 30 (Reuters) - Neovacs Sa  ALNEV.PA :
    * FY OPERATING LOSS EUR ‍​18.3 MILLION VERSUS LOSS OF EUR
17.3
MILLION YEAR AGO
    * FY REVENUE EUR ‍​0.8 MILLION VERSUS EUR 0.4 MILLION YEAR
AGO
    * FY NET LOSS EUR ‍​14.8 MILLION VERSUS LOSS OF EUR 13.9
MILLION
YEAR AGO
    * BASED ON POSITIVE OUTCOME OF IFN-ALPHA KINOID LUPUS STUDY,
INTENDS TO FILE FOR ORPHAN DRUG DESIGNATION IN SOUTH KOREA WITH
CKD IN 2018
    * ELIGIBLE TO RECEIVE MILESTONE PAYMENTS IN H2 FROM 3
INTERNATIONAL PARTNERS, PENDING POSITIVE RESULTS OF IFN-ΑLPHA
KINOID PHASE IIB CLINICAL TRIAL IN LUPUS
    * NEOSTELL PROJECT EXPECTED TO START IN H2 2018 AND BE
COMPLETED
IN 2023
    * AT DEC. 31, 2017, NEOVACS HAD CASH AND CASH EQUIVALENTS OF
EUR
5.1 MILLION
    * EXPECTS TO REPORT RESULTS OF PHASE IIB CLINICAL TRIAL IN
LUPUS
IN MID-2018

Source text for Eikon:  ID:nGNEf1tWM 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))